Your session is about to expire
← Back to Search
Mesenchymal Stem Cell Therapy
AstroStem-V for COVID-19 Pneumonia
Phase 1 & 2
Recruiting
Research Sponsored by Nature Cell Co. Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4, week 8, and week 12
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a treatment using special cells from donated fat tissue to help patients with severe COVID-19 lung infections. The cells aim to heal lung damage and reduce swelling, improving breathing. These special cells have shown promise in reducing lung damage and inflammation in COVID-19 patients, with several studies indicating improved survival and reduced mortality.
Eligible Conditions
- COVID-19 Pneumonia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 4, week 8, and week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4, week 8, and week 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Abnormalities of physical examination, vital signs, and laboratory test
Incidence of adverse events
Secondary study objectives
2019 nCOV nucleic acid test
Cognitive Therapy
Mortality rate
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: AstroStem-VExperimental Treatment1 Intervention
AstroStem-V which consists of three syringes and each syringe contains 1.0 x 10\^8 cells / 3mL of saline with 30% human serum
Find a Location
Who is running the clinical trial?
Nature Cell Co. Ltd.Lead Sponsor
4 Previous Clinical Trials
289 Total Patients Enrolled
JeongChan Ra, Ph.D.Study DirectorNature Cell Co. Ltd.
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a severe condition called shock that is not being controlled.You have a lung disease, but not COVID-19 pneumonia.You have a permanent brain injury or a history of cancer.The principal investigator believes you are not suitable for the study for reasons not mentioned before.You have moderate symptoms of COVID-19, such as feeling sick or having trouble breathing when you do physical activities.You have received stem cell treatment.You have severe kidney failure and need regular treatment, or you have liver cirrhosis with complications.You have a history of blood clots or high blood pressure in your lungs.Your doctor expects that you have less than 2 months to live because of your illness.You cannot take aspirin because it causes you discomfort or side effects.You have mild symptoms of COVID-19, such as normal breathing and oxygen levels, and a normal heart rate.
Research Study Groups:
This trial has the following groups:- Group 1: AstroStem-V
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger